David Lebwohl, EVP and Chief Medical Officer at Intellia Therapeutics ($NTLA), made one open market sale of common shares in the last 365 days, totaling about $110,000. His most recent sale occurred on January 5, 2026. These NTLA insider sales rank 9,432nd among 11,678 individual insiders in our database, where the average sale amount is $8.6 million across about 6.4 transactions. Lebwohl has no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | A | Common Stock | 9943 | $0.00 | 131,192.0000 | 115,829,926 | 8.20% | 0.01% |
| March 1, 2026 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | A | Stock Option (right to buy) | 14204 | $0.00 | 14,204.0000 | 115,829,926 | 9999.99% | 0.01% |
| Jan. 5, 2026 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | S | Common Stock | 11903 | $9.21 | 121,249.0000 | 115,829,926 | 8.94% | 0.01% |
| March 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | A | Common Stock | 43200 | $0.00 | 130,866.0000 | 103,517,460 | 49.28% | 0.04% |
| March 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | A | Stock Option (right to buy) | 61714 | $0.00 | 61,714.0000 | 103,517,460 | 9999.99% | 0.06% |
| Jan. 3, 2025 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | S | Common Stock | 9557 | $12.18 | 87,666.0000 | 0 | 9.83% | 0.00% |
| Jan. 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | M | Common Stock | 3189 | $0.00 | 97,223.0000 | 0 | 3.39% | 0.00% |
| Jan. 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | M | Restricted Stock Unit | 3189 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | A | Common Stock | 38701 | $0.00 | 93,073.0000 | 0 | 71.18% | 0.00% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | A | Stock Option (right to buy) | 55855 | $0.00 | 55,855.0000 | 0 | 9999.99% | 0.00% |
| Jan. 3, 2024 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | S | Common Stock | 5843 | $29.46 | 54,372.0000 | 0 | 9.70% | 0.00% |
| Jan. 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | M | Common Stock | 3187 | $0.00 | 60,215.0000 | 0 | 5.59% | 0.00% |
| Jan. 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | M | Restricted Stock Unit | 3187 | $0.00 | 3,189.0000 | 0 | 49.98% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | A | Common Stock | 30674 | $0.00 | 56,361.0000 | 0 | 119.41% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | A | Stock Option (right to buy) | 43342 | $0.00 | 43,342.0000 | 0 | 9999.99% | 0.00% |
| Jan. 4, 2023 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | S | Common Stock | 2574 | $37.21 | 25,687.0000 | 0 | 9.11% | 0.00% |
| Jan. 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | M | Restricted Stock Unit | 3187 | $0.00 | 6,376.0000 | 0 | 33.33% | 0.00% |
| Jan. 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Lebwohl David | EVP, Chief Medical Officer | M | Common Stock | 3187 | $0.00 | 28,261.0000 | 0 | 12.71% | 0.00% |